PREVENTION BUNDLES FOR SSIs (PREBUSSI).

Sponsor
Maximos Frountzas (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT05548764
Collaborator
(none)
200
14.9

Study Details

Study Description

Brief Summary

Surgical site infections (SSIs) are the most complication after a surgical operation and their incidence reaches 20% worldwide. SSIs have been associated to significant morbidity and mortality, high ICU admission rates, increased length of hospital stay, high readmission rates and raised cost. However, there is no registry for SSIs in Greece so far. In addition, it has been considered that almost half of SSIs could be prevented. Therefore, several prevention strategies have been suggested by international health organizations, such as WHO and NICE, that seem to be effective. The aim of the present study is to investigate the effect of 10 prevention bundles on the rate of SSIs, as well their consequences on several financial parameters of the Greek healthcare system.

Condition or Disease Intervention/Treatment Phase
  • Procedure: Prevention Bundles for SSIs

Detailed Description

  • 1st phase (2 months) → SSIs rate among abdominal surgical operations and reporting of patients' demographics (gender, age, comorbidities), type of surgery (upper GI, HPB, colorectal), surgical approach (open, laparoscopic), urgency classification, operation time, cost, pathogen cultures and antibiotic sensitivity test.

  • 2ο phase (10 months) → implementation of 10 prevention bundles:

  1. Antibiotic delivery 1-1.5 hours before surgical incision and repeat every 4 hours intraoperatively.

  2. Hair removal with electric hair clippers using single-use bladdes.

  3. Surgical scrub with Povidone Iodine solution 4% (Betadine Surgical Scrub)

  4. Skin preparation with chlorexidine alcohol-based antiseptic solution 2%.

  5. Intraoperative and postoperative (4-6 hours) normothermia (>36οC) using warmed forced-air blankets.

  6. Perioperative normoglycemia (Glu<200mg/dl) in diabetic patients.

  7. Single-use drapes and gowns.

  8. Surgical team glove changing by before skin incision closing.

  9. Single-layer surgical incision closure with triclosan plus antimicrobial-coated sutures.

  10. Wound irrigation (skin and subcutaneous fat) with Povidone Iodine solution (Betadine) after abdominal wall closure.

  • Implementation check of 10 prevention bundles preoperatively, intraoperatively and postoperatively.

  • Clinical assessment on POD 1, 3, 7 and 1 month postoperatively for SSI presence (according to WHO 2018 definition).

  • Reporting of patients' demographics (gender, age, comorbidities), type of surgery (upper GI, HPB, colorectal), surgical approach (open, laparoscopic), urgency classification, operation time, length of stay, cost, pathogen cultures and antibiotic sensitivity test.

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Case-Only
Time Perspective:
Prospective
Official Title:
PREVENTION BUNDLES FOR SURGICAL SITE INFECTIONS (PREBUSSI): a Multicenter Observational Study.
Anticipated Study Start Date :
Oct 1, 2022
Anticipated Primary Completion Date :
Oct 1, 2023
Anticipated Study Completion Date :
Dec 30, 2023

Arms and Interventions

Arm Intervention/Treatment
Prevention Bundles

Patients in which prevention bundles for SSIs have been implemented.

Procedure: Prevention Bundles for SSIs
10 preoperative, intraoperative and postoperative bundles that aim to decrease SSIs rate after their implementation in patients that underwent abdominal surgery.

No Prevention Bundles

Patients in which prevention bundles for SSIs have not been implemented.

Outcome Measures

Primary Outcome Measures

  1. Incidence of SSIs [30 days]

    Rate of SSIs after implementation of prevention bundles

Secondary Outcome Measures

  1. Length of hospital stay [30 days]

    Days of hospitalization.

  2. Cost [30 days]

    Overall cost of procedures and hospitalization.

  3. Pathogen cultures [30 days]

    Results of pathogen cultures.

  4. Antibiotic sensitivity test [30 days]

    Antibiotics in which cultured pathogens are sensitive.

  5. Implementation of guidelines [30 days]

    Adoptive efficacy of the 10 preventive bundles.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 99 Years
Sexes Eligible for Study:
All
Inclusion Criteria:
  1. Age ≥ 18 years old

  2. Signed consent from patient or authorized representative

  3. Abdominal surgery

  4. Open or laparoscopic operations

Exclusion Criteria:
  1. Age < 18 years old

  2. No signed consent from patient or authorized representative

  3. Neck, thoracic, anal, lumbar operations

  4. No closure of abdominal wall or open abdomen

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Maximos Frountzas

Investigators

  • Principal Investigator: Konstantinos G Toutouzas, MD PhD, National and Kapodistrian University of Athens

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:
Maximos Frountzas, Maximos Frountzas MD MPA PhD, National and Kapodistrian University of Athens
ClinicalTrials.gov Identifier:
NCT05548764
Other Study ID Numbers:
  • PREBUSSI 2022
First Posted:
Sep 21, 2022
Last Update Posted:
Sep 21, 2022
Last Verified:
Sep 1, 2022
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Maximos Frountzas, Maximos Frountzas MD MPA PhD, National and Kapodistrian University of Athens
Additional relevant MeSH terms:

Study Results

No Results Posted as of Sep 21, 2022